! believe what your saying is that the two year survival rate is 148 patients in NWBO trial at 45% survival rate blended. Due to the fact that NWBO trial has been running for MORE than two years. If 331 patients received SOC for gbm per American Brain Tumor Asscciation. 30% two year survival rate, for 331 patients, 110 alive. The comparison would be. 331 DCVax-L two year survival, blended 148 patients. SOC 331 patient 2 year survival 110 patients. Thus two year survival rate. DCVax-L blended verses SOC 148/110. What should get interesting in the future is DCVax-L treatment survival rates could go up even more. I believe this is the bet the folks are making here.
Market Data 
Markets 
AI
